SOPHiA GENETICS SA
SOPHHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeSOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. With a market capitalization of $625.7M, it sits in small-cap territory. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Market Cap
$625.7M
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-14.70
EPS (TTM)
$-1.16
EPS (Fwd)
$-0.50
ROE
-101.2%
ROA
-24.5%
Cash
$107.7M
Total Debt
$61.8M
Free CF
-$25.7M
52W Change
72.9%
Annual Financials
Cash vs Debt
Where SOPH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SOPH finished 5.36% above its 150-day moving average ($6.16) and 11.13% above its 200-day moving average ($5.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SOPH overbought or oversold?
At the October 20, 2026 close, SOPH's RSI(14) was 22.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SOPHiA GENETICS SA holds $107.7M in cash against $61.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$25.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -101.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $40.5M (2021) to $77.3M (2025), reflecting a 91% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SOPHiA GENETICS SA and its sector.